In the context of a Lanham Act case, CRA assessed whether market performance for a hospital-based pharmaceutical product was affected by alleged improper statements by a competitor. CRA’s causality analysis included consideration of other economic factors that affected product sales, including assessment of market preparation, launch, commercialization, and promotional efforts used to support the product that was allegedly affected by improper marketing support.
Dr. Alison Hole joins CRA's Antitrust & Competition Economics Practice
CRA is pleased to announce that Dr. Alison Hole has joined the company as a Vice President in the Antitrust & Competition Economics Practice.